CA3027118C - Compositions and methods for the treatment of cancer - Google Patents
Compositions and methods for the treatment of cancer Download PDFInfo
- Publication number
- CA3027118C CA3027118C CA3027118A CA3027118A CA3027118C CA 3027118 C CA3027118 C CA 3027118C CA 3027118 A CA3027118 A CA 3027118A CA 3027118 A CA3027118 A CA 3027118A CA 3027118 C CA3027118 C CA 3027118C
- Authority
- CA
- Canada
- Prior art keywords
- formula
- cancer
- administration
- compositions
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641022026 | 2016-06-28 | ||
| IN201641022026 | 2016-06-28 | ||
| IN201641025259 | 2016-07-22 | ||
| IN201641025259 | 2016-07-22 | ||
| IN201741006185 | 2017-02-21 | ||
| IN201741006185 | 2017-02-21 | ||
| PCT/IB2017/052814 WO2018002739A1 (en) | 2016-06-28 | 2017-05-12 | Compositions and methods for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3027118A1 CA3027118A1 (en) | 2018-01-04 |
| CA3027118C true CA3027118C (en) | 2023-08-15 |
Family
ID=60785109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3027118A Active CA3027118C (en) | 2016-06-28 | 2017-05-12 | Compositions and methods for the treatment of cancer |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10858349B2 (enExample) |
| EP (1) | EP3452044A4 (enExample) |
| JP (1) | JP6950972B2 (enExample) |
| KR (1) | KR102306412B1 (enExample) |
| CN (1) | CN109414438A (enExample) |
| AU (3) | AU2017286852B2 (enExample) |
| BR (1) | BR112018076257A2 (enExample) |
| CA (1) | CA3027118C (enExample) |
| IL (2) | IL263563A (enExample) |
| MX (1) | MX384144B (enExample) |
| RU (1) | RU2770081C2 (enExample) |
| SG (1) | SG11201810947PA (enExample) |
| WO (1) | WO2018002739A1 (enExample) |
| ZA (1) | ZA201808232B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202100411TA (en) * | 2018-08-03 | 2021-02-25 | Cellix Bio Private Ltd | Compositions and methods for the treatment of cancer |
| EP3679952A1 (en) * | 2019-01-10 | 2020-07-15 | Université de Strasbourg | Nanoemulsions encapsulating prodrugs |
| MX2022014094A (es) * | 2020-05-19 | 2022-12-08 | Cellix Bio Private Ltd | Formulaciones farmaceuticas y sus preparaciones para el tratamiento del cancer. |
| WO2022043902A1 (en) * | 2020-08-29 | 2022-03-03 | Cellix Bio Private Limited | Process for the preparation of derivatives of 5-fluoro pyrimidines used as anti cancer agents |
| WO2022049462A1 (en) * | 2020-09-05 | 2022-03-10 | Cellix Bio Private Limited | Process for the preparation of derivatives of 5-fluoro pyrimidines used as anti cancer agents |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968914A (en) * | 1987-10-28 | 1999-10-19 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| CA1327358C (en) * | 1987-11-17 | 1994-03-01 | Morio Fujiu | Fluoro cytidine derivatives |
| TW254946B (enExample) * | 1992-12-18 | 1995-08-21 | Hoffmann La Roche | |
| JPH1192386A (ja) * | 1997-09-17 | 1999-04-06 | Nikken Chem Co Ltd | ５−フルオロウリジン誘導体を有効成分とする抗癌剤 |
| WO2002011668A2 (en) | 2000-08-09 | 2002-02-14 | Kolon Industries, Inc. | 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients |
| WO2010047866A2 (en) * | 2008-08-01 | 2010-04-29 | Dow Agrosciences Llc | Use of 5-fluorocytosine as a fungicide |
| EP2393472B1 (en) * | 2008-12-05 | 2019-06-05 | NanoMed Holdings Pty Ltd | Amphiphile prodrugs |
| US10463684B2 (en) * | 2014-01-29 | 2019-11-05 | Board Of Regents, The Uneversety Of Texas System | Nucleobase analogue derivatives and their applications |
| GB201419015D0 (en) * | 2014-10-24 | 2014-12-10 | Orca Pharmaceuticals Ltd | Compounds |
-
2017
- 2017-05-12 CN CN201780037213.3A patent/CN109414438A/zh active Pending
- 2017-05-12 KR KR1020197002186A patent/KR102306412B1/ko not_active Expired - Fee Related
- 2017-05-12 AU AU2017286852A patent/AU2017286852B2/en not_active Ceased
- 2017-05-12 SG SG11201810947PA patent/SG11201810947PA/en unknown
- 2017-05-12 WO PCT/IB2017/052814 patent/WO2018002739A1/en not_active Ceased
- 2017-05-12 US US16/307,324 patent/US10858349B2/en not_active Expired - Fee Related
- 2017-05-12 JP JP2018567812A patent/JP6950972B2/ja not_active Expired - Fee Related
- 2017-05-12 CA CA3027118A patent/CA3027118C/en active Active
- 2017-05-12 MX MX2019000279A patent/MX384144B/es unknown
- 2017-05-12 BR BR112018076257-1A patent/BR112018076257A2/pt not_active IP Right Cessation
- 2017-05-12 RU RU2019100713A patent/RU2770081C2/ru active
- 2017-05-12 EP EP17819434.6A patent/EP3452044A4/en not_active Withdrawn
-
2018
- 2018-12-06 IL IL263563A patent/IL263563A/en unknown
- 2018-12-06 ZA ZA2018/08232A patent/ZA201808232B/en unknown
-
2020
- 2020-09-30 US US16/948,770 patent/US20210078983A1/en not_active Abandoned
-
2021
- 2021-02-02 IL IL280587A patent/IL280587B/en unknown
- 2021-06-07 AU AU2021203748A patent/AU2021203748A1/en not_active Abandoned
-
2023
- 2023-07-27 AU AU2023208158A patent/AU2023208158A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019100713A3 (enExample) | 2021-02-08 |
| IL280587A (en) | 2021-03-25 |
| MX2019000279A (es) | 2019-08-01 |
| BR112018076257A2 (pt) | 2019-03-26 |
| AU2017286852B2 (en) | 2021-05-06 |
| IL280587B (en) | 2021-10-31 |
| AU2017286852A1 (en) | 2019-01-17 |
| RU2770081C2 (ru) | 2022-04-14 |
| RU2019100713A (ru) | 2020-07-28 |
| MX384144B (es) | 2025-03-14 |
| NZ749512A (en) | 2021-08-27 |
| KR20190034539A (ko) | 2019-04-02 |
| AU2023208158A1 (en) | 2023-08-17 |
| JP6950972B2 (ja) | 2021-10-20 |
| CA3027118A1 (en) | 2018-01-04 |
| US20190292171A1 (en) | 2019-09-26 |
| SG11201810947PA (en) | 2019-01-30 |
| EP3452044A1 (en) | 2019-03-13 |
| EP3452044A4 (en) | 2020-04-22 |
| JP2019519563A (ja) | 2019-07-11 |
| KR102306412B1 (ko) | 2021-09-28 |
| IL263563A (en) | 2019-01-31 |
| CN109414438A (zh) | 2019-03-01 |
| US10858349B2 (en) | 2020-12-08 |
| ZA201808232B (en) | 2019-09-25 |
| US20210078983A1 (en) | 2021-03-18 |
| AU2021203748A1 (en) | 2021-07-08 |
| WO2018002739A1 (en) | 2018-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023208158A1 (en) | Compositions and methods for the treatment of cancer | |
| WO2016046675A1 (en) | Compositions and methods for the treatment of neurological diseases | |
| WO2017090007A1 (en) | Compositions and methods for the treatment of urea cycle disorders and hepatic diseases | |
| US20160332950A1 (en) | Compositions and methods for the treatment of urea cycle disorders and gout | |
| WO2016046674A1 (en) | Compositions and methods for the treatment of moderate to severe pain | |
| AU2019313484A2 (en) | Compositions and methods for the treatment of cancer | |
| WO2017221083A1 (en) | Compositions and methods for the treatment of viral infections | |
| EP3240779B1 (en) | Compositions and methods for the treatment of epilepsy and neurological disorders | |
| US9932294B2 (en) | Compositions and methods for the treatment of multiple sclerosis | |
| EP3212626B1 (en) | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis | |
| NZ749512B2 (en) | Compositions and methods for the treatment of cancer | |
| WO2014060942A2 (en) | Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases | |
| WO2016132186A1 (en) | Compositions and methods for the treatment of hyperglycemia and metabolic syndrome | |
| WO2016203337A2 (en) | Compositions and methods for the treatment of cancer | |
| WO2016203352A2 (en) | Compositions and methods for the treatment of cancer | |
| WO2016046670A1 (en) | Compositions and methods for the treatment of renal diseases | |
| WO2016046672A1 (en) | Compositions and methods for the treatment of cardiovascular diseases and diabetes | |
| WO2016067297A1 (en) | Salts of valproic acid with piperazine, ethylenediamine, lysine and/or eicosapentaenoic ecid (epa) amine derivatives for the treatment of epilepsy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220510 |
|
| H13 | Ip right lapsed |
Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE Effective date: 20251108 |
|
| H11 | Ip right ceased following rejected request for revival |
Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED Effective date: 20251113 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251113 |